1022 ECP Be Bio
BioCentury & Getty Images

Emerging Company Profile

Be Bio: bringing the B to cell therapy 

Be Biopharma is engineering B cells to secrete therapeutic proteins

Be Biopharma is engineering B cells to secrete therapeutic proteins.

Oct 23, 2020 | 12:40 AM GMT

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of

Read the full 744 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE